These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32245533)

  • 1. Long-Term Management: Modern Measures to Prevent Readmission in Patients with Hepatic Encephalopathy.
    Rosenblatt R; Yeh J; Gaglio PJ
    Clin Liver Dis; 2020 May; 24(2):277-290. PubMed ID: 32245533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy.
    Vadhariya A; Chen H; Serna O; Zamil H; Abughosh SM
    Medicine (Baltimore); 2020 Apr; 99(16):e19603. PubMed ID: 32311928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.
    Frenette CT; Levy C; Saab S
    Dig Dis Sci; 2022 Jun; 67(6):1994-2004. PubMed ID: 34169435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach.
    Yanny B; Winters A; Boutros S; Saab S
    Clin Liver Dis; 2019 Nov; 23(4):607-623. PubMed ID: 31563214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis.
    Louissaint J; Grzyb K; Bashaw L; Mohammad RA; Parikh ND; Tapper EB
    Am J Gastroenterol; 2022 Mar; 117(3):491-494. PubMed ID: 35020619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.
    Tapper EB; Finkelstein D; Mittleman MA; Piatkowski G; Chang M; Lai M
    Clin Gastroenterol Hepatol; 2016 May; 14(5):753-9. PubMed ID: 26407750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy.
    Stoll AM; Guido M; Pence A; Gentene AJ
    Ann Pharmacother; 2023 Feb; 57(2):133-140. PubMed ID: 35658580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Health Care Burden of Hepatic Encephalopathy.
    Elsaid MI; John T; Li Y; Pentakota SR; Rustgi VK
    Clin Liver Dis; 2020 May; 24(2):263-275. PubMed ID: 32245532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
    Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
    World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
    Mekky MA; Riad AR; Gaber MA; Abdel-Malek MO; Swifee YM
    Arab J Gastroenterol; 2018 Jun; 19(2):76-79. PubMed ID: 29935863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the modern management of hepatic encephalopathy.
    Bajaj JS
    Aliment Pharmacol Ther; 2010 Mar; 31(5):537-47. PubMed ID: 20002027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic encephalopathy: pathophysiology and emerging therapies.
    Sundaram V; Shaikh OS
    Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
    Neff G; Zachry W
    Pharmacoeconomics; 2018 Jul; 36(7):809-822. PubMed ID: 29651649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.
    Patidar KR; Bajaj JS
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2048-61. PubMed ID: 26164219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.